Literature DB >> 31221532

Osteoporosis and vascular calcification: A shared scenario.

María Carmen García-Gómez1, Gemma Vilahur2.   

Abstract

Osteoporosis is a systemic skeletal disease, characterised by low bone mass and deterioration in the micro-architecture of bone tissue, which causes increased bone fragility and consequently greater susceptibility to fractures. It is the most frequent metabolic bone disease in our population, and fractures resulting from osteoporosis are becoming more common. Furthermore, vascular calcification is a recognised risk factor of cardiovascular morbidity and mortality that historically has been considered a passive and degenerative process. However, it is currently recognised as an active process, which has histopathological characteristics, mineral composition and initiation and development mechanisms characteristic of bone formation. Paradoxically, patients with osteoporosis frequently show vascular calcifications. Traditionally, they have been considered as independent processes related to age, although more recent epidemiological studies have shown that there is a close relationship between the loss of bone mass and vascular calcification, regardless of age. In fact, both conditions share risk factors and pathophysiological mechanisms. These include the relationship between proteins of bone origin, such as osteopontin and osteoprotegerin (OPG), with vascular pathology, and the intercellular protein system RANK/RANKL/OPG and the Wnt signalling pathway. The mechanisms linked in both pathologies should be considered in clinical decisions, given that treatments for osteoporosis could have unforeseen effects on vascular calcification, and vice versa. In short, a better understanding of the relationship between both entities can help in proposing strategies to reduce the increasing prevalence of vascular calcification and osteoporosis in the aging population.
Copyright © 2019 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Bone fractures; Calcificación vascular; Cardiovascular diseases; Enfermedad cardiovascular; Fracturas óseas; Osteoporosis; RANK/RANKL/OPG; Vascular calcification; Vía de señalización Wnt; Wnt signalling pathway

Year:  2019        PMID: 31221532     DOI: 10.1016/j.arteri.2019.03.008

Source DB:  PubMed          Journal:  Clin Investig Arterioscler        ISSN: 0214-9168


  6 in total

1.  Effect of vitamin D supplementation on OPG/RANKL signalling activities in endothelial tissue damage in diet-induced diabetic rat model.

Authors:  Gizem Celebi; Merve Anapali; Fatma Kaya Dagistanli; Ayse Seda Akdemir; Duygu Aydemir; Nuriye Nuray Ulusu; Turgut Ulutin; Evrim Komurcu-Bayrak
Journal:  Pharmacol Rep       Date:  2021-10-16       Impact factor: 3.024

2.  Relationship between ectopic calcifications and bone fragility depicted on computed tomography scan in 70 patients with systemic sclerosis.

Authors:  Marine Fauny; Elodie Bauer; Edem Allado; Eliane Albuisson; Joëlle Deibener; François Chabot; Damien Mandry; Olivier Huttin; Isabelle Chary-Valckenaere; Damien Loeuille
Journal:  J Scleroderma Relat Disord       Date:  2022-06-28

Review 3.  Role of m6A in osteoporosis, arthritis and osteosarcoma (Review).

Authors:  Yibo Hu; Xiaohui Zhao
Journal:  Exp Ther Med       Date:  2021-06-30       Impact factor: 2.447

4.  Identification of circRNA-associated ceRNA network in BMSCs of OVX models for postmenopausal osteoporosis.

Authors:  Huichao Wang; Kaifeng Zhou; Fangzhu Xiao; Zhongyue Huang; Jun Xu; Guangnan Chen; Youwen Liu; Huijie Gu
Journal:  Sci Rep       Date:  2020-07-02       Impact factor: 4.379

5.  Hypertension is associated with osteoporosis: a case-control study in Chinese postmenopausal women.

Authors:  Hao Chai; Jirong Ge; Li Li; Jianyang Li; Yunjin Ye
Journal:  BMC Musculoskelet Disord       Date:  2021-03-07       Impact factor: 2.362

6.  Resveratrol Ameliorates Aortic Calcification in Ovariectomized Rats via SIRT1 Signaling.

Authors:  Sally K Hammad; Rana G Eissa; Mohamed A Shaheen; Nahla N Younis
Journal:  Curr Issues Mol Biol       Date:  2021-09-05       Impact factor: 2.976

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.